Trial Profile

A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PBI-200 (Primary) ; Ritonavir
Indications Brain cancer; Glioma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Pyramid Biosciences

Most Recent Events

12 Mar 2024 Status changed from active, no longer recruiting to discontinued.
28 Nov 2023 Status changed from recruiting to active, no longer recruiting.
08 Sep 2023 Planned number of patients changed from 74 to 91.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com